Phase 4 N=98 Assessing Pyridium for Post-Sling Urinary Retention
Urinary Retention
Primary: Number of Participants Considered to Have Passed Their Voiding Trial — 30; 30 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
Thrombosis
Primary: The Number of Subjects With Treatment-emergent Adverse Events (TEAEs) Will be Summarized Using Frequency Counts. — 0; 0; 0; 3 Participants
Phase 3 N=61 Early Levothyroxine Post Radioactive Iodine
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
Early Phase 1 N=60 Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
Chronic Graft Versus Host Disease
Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373
Phase 2 N=9 Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Neuroblastoma · Sarcoma
Primary: Objective Response Rate
N/A N=120 Effectiveness of Interventions to Teach Respiratory Inhaler Technique (E-TRaIN)
Asthma · Chronic Obstructive Pulmonary Disease (COPD)
Primary: Percentage of Participants With MDI Misuse From Baseline to 30 Days Post-Discharge — 92; 84; 11; 60 percentage
Phase 3 N=562 Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
HER2-positive Carcinoma of Breast
Primary: The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless…
Phase 4 N=122 Contrast Nephropathy and Nitrates
Contrast Induced Nephropathy
Primary: Change in GFR — 1.8; -4.1 mL/min
Phase 4 N=120 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification
Cataracts
Primary: Pharmacokinetics in Aqueous Humor Samples. — 443.07; 56.4525 ng/ml
Phase 4 N=50 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease
Liver Disease
Primary: Number of Participants That Reached Targeted International Normalized Ratio (INR) Within ±0.1 After First Fresh Frozen Plasma (FFP) Transfusion Completed. — 7; 17…
Phase 4 N=52 Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
Breast Cancer
Primary: Overall Number of Participants by the Number of Serious Adverse Events Reported Per Participant — 31; 17; 14; 21 Participants
Phase 2 N=11 Mitochondria and Chronic Kidney Disease
Hemodialysis-Induced Symptom · Mitochondrial Diseases
Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds
Phase 3 N=794 A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream
Psoriasis Vulgaris
Primary: Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8 — 121; 67; 4 Count…
Phase 2 N=195 Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Carcinoma, Squamous Cell of Head and Neck
Primary: Comparison of Progression Free Survival (PFS) Between Treatment Groups Using irRECIST and Evaluated by Independent Radiology. — 185; 181 days — p=0.266
Phase 3 N=208 Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee
Osteoarthritis of the Knee
Primary: Total Number of Treatment Emergent Adverse Events (TEAEs) in Patients With Symptomatic Osteoarthritis (OA) of the Knee Who Received Two Doses of 32 mg FX006 — 336 TEAEs